Antibody drug conjugates : lessons from 20 years of clinical experience
Cet article analyse les difficultés rencontrées durant ces 20 dernières années dans le développement des conjugués anticorps-médicament, puis présente les principaux enseignements de ces échecs ainsi que des solutions possibles
Antibody drug conjugates are complex delivery systems for selective delivery of cytotoxic payloads. Yet despite the potential for this therapeutic platform and hundreds of clinical studies only three ADCs have been approved by regulatory agencies and only two are currently marketed. The difficulties for this class of compounds are both categorized and explored in this review, and potential solutions identified.
Annals of Oncology , résumé, 2016